Apotex Inc.
Apotex Inc. (Canada) holds 50 active US FDA Type II Drug Master Files and 2 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 1 FDA-registered manufacturing site. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Apotex Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/apotex-inc
Overview
Apotex Inc. is a Canadian pharmaceutical company that produces a wide range of affordable and high-quality generic medications. It is a leader in research and development of innovative pharmaceutical solutions.
Core services & business areas
Active ingredients with DMF or CEP filings
Substances for which Apotex Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Apotex Inc. holds 50 active (52 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- VILOXAZINE HYDROCHLORIDEActive2024-11-07
- OLANZAPINE FORM II USPActive2022-07-28
- FLUTICASONE PROPIONATE USP (MICRONIZED)Active2020-12-30
- BREXPIPRAZOLEActive2019-03-11
- ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE USPActive2018-11-02
- PALBOCICLIBActive2018-07-25
- ELIGLUSTAT TARTRATE (1:0.5)Active2018-05-01
- TOFACITINIB CITRATEActive2018-03-29
- TREPROSTINIL DIETHANOLAMINEActive2017-10-05
- TASIMELTEONActive2017-07-31
- BULK EVEROLIMUSActive2016-10-27
- POSACONAZOLEActive2016-03-31
- AXITINIBActive2015-10-10
- OLANZAPINE USPActive2015-06-22
- DEXLANSOPRAZOLE ANHYDRATEActive2015-03-30
- RUFINAMIDE USPActive2015-03-27
- RIVAROXABANActive2014-12-31
- VILAZODONE HYDROCHLORIDE BENZYL ALCOHOL MONOSOLVATEActive2014-07-18
- DABIGATRAN ETEXILATE MESYLATEActive2014-03-28
- TACROLIMUS USPActive2014-03-17
- BUDESONIDE USPActive2013-11-01
- DARIFENACIN HYDROBROMIDEActive2013-08-23
- SIROLIMUS DRUG SUBSTANCEActive2013-02-27
- ERLOTINIB HYDROCHLORIDEActive2013-01-22
- ADEFOVIR DIPIVOXILActive2012-12-07
- DESVENLAFAXINE SUCCINATE MONOHYDRATEActive2012-02-13
- PALIPERIDONE USPActive2011-06-24
- SITAGLIPTIN PHOSPHATE MONOHYDRATE USPActive2010-10-08
- ABACAVIR SULFATE USPActive2010-03-19
- MONTELUKAST SODIUM USPActive2010-01-29
- ANASTROZOLE USPActive2009-12-01
- MYCOPHENOLATE SODIUM USPActive2009-05-28
- CEVIMELINE HYDROCHLORIDE HEMIHYDRATEActive2009-02-06
- RIVASTIGMINE TARTRATEActive2008-12-04
- OLANZAPINE USPActive2008-09-17
- RISEDRONATE SODIUM HEMIPENTAHYDRATE USPActive2008-07-18
- ATORVASTATIN CALCIUM PROPYLENE GLYCOL SOLVATE USPActive2008-04-29
- PAROXETINE HYDROCHLORIDE ANHYDROUS USPActive2008-03-18
- MEMANTINE HYDROCHLORIDE USPActive2007-12-21
- ALFUZOSIN HYDROCHLORIDE USPActive2007-06-08
- ATOMOXETINE HYDROCHLORIDE USPActive2007-05-18
- IBANDRONATE SODIUMActive2007-05-11
- ARIPIPRAZOLE USPActive2006-11-13
- MOEXIPRIL HYDROCHLORIDE USPActive2006-01-18
- MIDODRINE HYDROCHLORIDE USPActive2005-06-30
- ZIPRASIDONE HYDROCHLORIDEActive2005-02-03
- ALENDRONATE SODIUM TRIHYDRATE USPActive2001-04-30
- CYCLOSPORINE USP (BULK)Active1999-01-04
- WARFARIN SODIUM CLATHRATE USPActive1995-03-15
- DEFERIPRONEActive1994-04-12
Showing the 50 most relevant of 52 Drug Master Files (active first). The full list is in the FDA DMF list.
Excipient Drug Master Files
Apotex Inc. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- POLYQUATERNIUM-1Active2017-03-08
Registered manufacturing sites (1)
Physical sites registered with the US FDA and resolved to Apotex Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2026-10-07
Failed dissolution specifications.
- recall — Class II2026-09-02
Failed Dissolution Specifications; product failed to meet 24-month stability testing acceptance criteria
- recall — Class II2026-04-22
Defective container: defect in a batch of bottle caps, specifically involving dislodged or missing cap liners.
- recall — Class II2026-03-25
Lack of Assurance of Sterility
- warning_letter2025-10-31
FDA Warning Letter (drug product)
- recall — Class II2025-10-08
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
- recall — Class II2025-10-08
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
- recall — Class II2025-07-02
Lack of Assurance of Sterility
- recall — Class II2025-07-02
Lack of Assurance of Sterility
- recall — Class II2025-07-02
Lack of Assurance of Sterility
- recall — Class II2025-06-11
Defective Container: This recall is being initiated due to a leaking unit stored horizontally.
- 4832025-05-09
Validation lacking for sterile drug products
- 4832025-05-09
Written in-process control procedures
- 4832025-05-09
Complaint Handling Procedure
- 4832025-05-09
Computer control of master formula records
- 4832025-05-09
Investigations of discrepancies, failures
- 4832025-05-09
Absence of Written Procedures
- 4832025-05-09
Following/documenting laboratory controls
- 4832025-05-09
Cleaning / Sanitizing / Maintenance
- 4832025-05-09
Procedures for sterile drug products
- 4832025-05-09
Equipment to control conditions
- recall — Class II2024-02-28
CGMP Deviations: potential presence of Burkholderia cepacia complex
- recall — Class II2023-12-06
Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine
- recall — Class II2023-12-06
Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine
- recall — Class II2023-12-06
Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine
- recall — Class II2023-12-06
Failed Impurities/Degradation Specifications-Out of specification (OOS) results for the excipient Amadori Glucose adduct of Paroxetine
- recall — Class II2023-05-17
Presence of Foreign Substance: Glass splinter particle entrapped inside the pump ball seat rendered the pump inoperable.
- recall — Class II2023-03-15
Lack of sterility assurance: Cracks have developed in some of the units caps of Brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility.
- recall — Class III2023-01-04
Failed Stability Specifications: Out of specification for weight loss at the 18-month stability timepoint and projected weight loss of 21.1% at shelf life.
- 4832022-09-14
Procedures for sterile drug products
- recall — Class II2022-07-27
Failed dissolution specifications: OOS for dissolution at the 12-month stability time point.
- recall — Class III2022-05-25
Failed Dissolution Specifications: Sirolimus Oral Solution recalled due to lot RZ1598 exceeded the specification limit at the 14-month timepoint.
- recall — Class II2021-04-14
Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate
- recall — Class I2021-02-17
Labeling; Label Mixup; syringe barrels may containing markings for 150 mg/mL (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength)
- recall — Class I2021-02-17
Labeling; Label Mixup; syringe barrels may contain markings for 100 mg/mL (corresponding to 100 mg/mL strength) instead of 150 mg/mL (corresponding to 120 mg/0.8mL strength)
- recall — Class II2020-11-25
Failed Dissolution Specifications: Out of specification for dissolution.
- recall — Class II2020-06-24
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levels
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class II2019-11-20
GGMP Deviations: Possible contamination with impurity N-nitrosodimethylamine (NDMA).
- recall — Class III2019-11-06
Presence of Foreign Tablets/Capsules: a single tablet of Pravastatin 40 mg found in bottle of Atorvastatin Calcium 40 mg.
- recall — Class II2019-03-13
Contraceptive Tablets Out of Sequence: Missing or incorrect tablet placement.
- recall — Class II2018-06-13
Presence of foreign substance: glass particles
- recall — Class I2018-05-23
Subpotent Drug: High Levels of Impurities Resulting in Decrease Potency
- recall — Class I2018-05-23
Subpotent Drug: High Levels of Impurities Resulting in Decrease Potency
- 4832017-04-11
Validation lacking for sterile drug products
- 4832017-04-11
Investigations of discrepancies, failures
Is this Apotex Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.